A W.A.R.E. (Amevive Wisdom Acquired from Real World Evidence) is an ongoing multicenter, phase 4 clinical study in Canada in patients with psoriasis treated with alefacept. Generation of a real-time database has several advantages, including networking among sites, development of a “best practices” model, and the optimization of the use of alefacept for Canadian patients with moderate to severe psoriasis.

This is the first report of this ongoing study, in which we present the preliminary results of 362 patients recruited from 36 Canadian dermatology clinics enrolled in the A.W.A.R.E. study (from May 2005 to July 2007). The majority of the patients (85%) received the standard 12-week alefacept course.

CONCLUSIONS

Key findings from the baseline characteristics of patients with psoriasis enrolled in the A.W.A.R.E. study:
- Treatment with alefacept was most frequently initiated in subjects with greater than 10% BSA involvement.
- Lack of adequate response to previous psoriasis therapy was the leading cause of initiating treatment with alefacept.
- The initial treatment strategy for most patients involved adding alefacept to their current regimen.
- The A.W.A.R.E. study offers an opportunity to study the use of alefacept in clinical practice and will bring new insights to future research initiatives.

REFERENCES


Presented at the 21st World Congress of Dermatology, 25th September–October 3, 2007
Buenos Aires, Argentina

The A.W.A.R.E. study is sponsored by Astellas Pharma Canada, Inc., which also provided the funding for the preparation of the poster.